CureVac Shareholders Face Pivotal Merger Vote

The future of CureVac as an independent entity now rests in shareholders’ hands as a decisive vote approaches. Investors will determine whether to approve a transformative acquisition by competitor BioNTech, marking a critical juncture for the pioneering mRNA company. With the deal’s completion pending final approval, stakeholders face a binary outcome that could either revitalize the biotech firm or conclude its standalone operations.

BioNTech has proposed an all-stock transaction valuing CureVac at approximately €1.25 billion. Should shareholders endorse the arrangement during the extraordinary general meeting scheduled for November 25, 2025, in Amsterdam, CureVac investors would receive a 4-6% stake in the combined entity. This valuation follows extensive restructuring efforts throughout 2024 and represents a strategic consolidation Read more...